European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
This research is focused on children and young people with a type of cancer called classical Hodgkin lymphoma. While treatment is often very successful, some patients unfortunately relapse or find their cancer hard to treat. This study aims to find new, gentler ways to keep an eye on the cancer and how well treatment is working, using simple blood tests. These tests look for small amounts of cancer DNA in the blood, known as ctDNA. The goal is to help doctors better understand who might need more intensive treatment and who might need less, reducing side effects and improving long-term health. This could lead to more personalised and effective care for young patients.
At a glance
What is this study about?
Classical Hodgkin lymphoma is a type of cancer that can affect children and young people. While treatments have improved a lot, some patients still find their cancer comes back or doesn't respond as well as hoped. Doctors want to find out who these patients are earlier, so they can adjust treatment to give them the best chance of getting better.
Currently, doctors use scans like PET/CT to see how the cancer is doing. While these are helpful, they don't always give the full picture. This study is exploring a new way called a "liquid biopsy." This involves taking a simple blood test to look for tiny pieces of DNA that have come from the cancer cells, called circulating tumour DNA (ctDNA). Think of it like finding fingerprints left behind by the cancer.
By finding these tiny bits of cancer DNA, doctors hope to get more detailed information about the cancer. This could help them know early on if a treatment is working really well, or if it needs to be made stronger. It might also help identify patients who could have less intense treatment, reducing side effects and improving their quality of life. Ultimately, this research aims to make cancer treatment for young people with Hodgkin lymphoma even more precise and effective.
Key takeaways
- This study aims to improve care for children and young people with Hodgkin lymphoma.
- It uses simple blood tests to find tiny bits of cancer DNA (ctDNA).
- This could help doctors know if treatment is working well or needs adjusting.
- The goal is more personalised treatment and fewer side effects.
- Participation involves blood samples, not new medicines.
- It could lead to better long-term health for patients.
Who may be eligible?
This study is looking for children and young adults under the age of 25 who have been diagnosed with a specific type of cancer called classical Hodgkin lymphoma. You would need to have this diagnosis confirmed by a doctor.
For you to be considered, you or your parent/guardian (depending on your age) would need to give your informed consent, meaning you understand the study and agree to take part. Also, you must be part of a social security scheme, like the NHS in the UK, or be a beneficiary of one.
However, some things would mean you couldn't join the study. For example, if you've already had chemotherapy or radiotherapy for another type of cancer, or if you've had treatment for Hodgkin lymphoma already (unless it was a short course of steroids for a specific reason). You also can't be in the study if you have a different rare type of Hodgkin lymphoma, another cancer, or if you live outside of the countries taking part where it would be difficult to keep track of your long-term health.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you under 25 years old?
- Do you have classical Hodgkin lymphoma?
- Have you started any Hodgkin lymphoma treatment yet (apart from short-term steroids)?
- Do you have another type of cancer?
- Are you part of a social security scheme (e.g., NHS in the UK)?
What does participation involve?
The information provided does not fully describe what taking part involves specifically for patients. However, based on the study's aim to use liquid biopsies, it would likely involve providing blood samples at various times during your standard cancer treatment and follow-up. These blood samples would be used to look for cancer DNA. The study focuses on monitoring an existing treatment, so it's unlikely to involve new medications just for the study. The total duration would depend on how long your standard treatment and follow-up last.
Potential risks and benefits
Locations (1)
- Pediatric Hematology and Oncology DepartmentVerified postcodeParis, France· Recruiting
Common questions
What is classical Hodgkin lymphoma?
It's a type of cancer that affects the lymphatic system, which is part of your body's immune system. It can make lymph nodes swell.
What is a 'liquid biopsy'?
It's a simple blood test that can find tiny bits of cancer DNA that are shed into your bloodstream from the tumour. It's much less invasive than taking a tissue sample.
Why is this study important?
It could help doctors understand how well cancer treatments are working for young people, and who might need different or adjusted care, leading to better results and fewer side effects.
Will I get new medicines as part of this study?
No, this study is about monitoring your existing treatment using blood tests, not about giving you new medicines.
Can my regular doctor still treat me if I join this study?
Yes, your regular doctors will continue to manage your care and treatment as usual. This study adds an extra way to gather information.
How to find out more
Mathieu SIMONIN, Medical Doctor
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.